leukapheresis

Summary

Summary: The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.

Top Publications

  1. ncbi Modification of the leukapheresis procedure for use in rhesus monkeys (Macaca mulata)
    Naohide Ageyama
    The Corporation for Production and Research of Laboratory Primates, Ibaraki, Japan
    J Clin Apher 18:26-31. 2003
  2. ncbi Monocyte enrichment from leukapheresis products by using the Elutra cell separator
    Sinyoung Kim
    Department of Laboratory Medicine, Yonsei Cell Therapy Center, Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea
    Transfusion 47:2290-6. 2007
  3. ncbi Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
    J D Geiger
    Department of Surgery, Section of Pediatric Surgery, Section of General Surgery, the Tumor Immunology and Immunotherapy Program, Ann Arbor, Michigan 48109 0245, USA
    Cancer Res 61:8513-9. 2001
  4. ncbi Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis
    M R Boulassel
    Immunodeficiency Service, Royal Victoria Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    J Clin Apher 18:55-60. 2003
  5. ncbi Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells
    J F Abrahamsen
    Division of Hematology, Department of Medicine, The Blood Bank, Haukeland University Hospital, and The University of Bergen, Bergen, Norway
    Transfusion 45:248-53. 2005
  6. ncbi Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34+ cell recovery
    Claudia Del Fante
    Servizio di Immunoematologia, Medicina Trasfusionale, Centro di Immunologia dei Trapianti, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    Stem Cells Dev 14:734-9. 2005
  7. ncbi Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient
    I Ohsawa
    Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
    Clin Nephrol 68:121-4. 2007
  8. ncbi Positive immunomagnetic CD34(+) cell selection in haplo-identical transplants in beta-thalassemia patients: removal of platelets using an automated system
    Francesco Zinno
    Immunohematology Section, Tor Vergata University and SIMT Bambino Gesù Pediatric Hospital, Rome, Italy
    Cytotherapy 12:60-6. 2010
  9. ncbi Mobilization of peripheral blood stem cells
    Onder Arslan
    Ankara University, Department of Hematology, Blood Bank and Apheresis Unit, Ankara, Turkey
    Transfus Apher Sci 37:179-85. 2007
  10. ncbi Why is leukocytapheresis effective in inflammatory bowel diseases?
    Yutaka Kohgo
    J Gastroenterol 39:1226-7. 2004

Detail Information

Publications213 found, 100 shown here

  1. ncbi Modification of the leukapheresis procedure for use in rhesus monkeys (Macaca mulata)
    Naohide Ageyama
    The Corporation for Production and Research of Laboratory Primates, Ibaraki, Japan
    J Clin Apher 18:26-31. 2003
    One of the most serious problems in applying leukapheresis to human infants is the large extracorporeal blood volume (ECV), resulting in substantial loss of platelets and red blood cells (RBCs)...
  2. ncbi Monocyte enrichment from leukapheresis products by using the Elutra cell separator
    Sinyoung Kim
    Department of Laboratory Medicine, Yonsei Cell Therapy Center, Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea
    Transfusion 47:2290-6. 2007
    ..This study evaluated a large-scale monocyte enrichment procedure with a commercially available cell separator (Elutra, Gambro BCT) and analyzed the capacity of enriched monocytes to differentiate into DCs...
  3. ncbi Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
    J D Geiger
    Department of Surgery, Section of Pediatric Surgery, Section of General Surgery, the Tumor Immunology and Immunotherapy Program, Ann Arbor, Michigan 48109 0245, USA
    Cancer Res 61:8513-9. 2001
    ..Fifteen patients (ages 3-17 years) were enrolled with 10 patients completing all vaccinations. Leukapheresis yields averaged 2.8 x 10(8) peripheral blood mononuclear cells (PBMC)/kg, and DC yields averaged 10...
  4. ncbi Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis
    M R Boulassel
    Immunodeficiency Service, Royal Victoria Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    J Clin Apher 18:55-60. 2003
    ..tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4(+) cell count >200 x 10(6)/l...
  5. ncbi Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells
    J F Abrahamsen
    Division of Hematology, Department of Medicine, The Blood Bank, Haukeland University Hospital, and The University of Bergen, Bergen, Norway
    Transfusion 45:248-53. 2005
    Large-volume leukapheresis (LVL) differs from normal-volume leukapheresis (NVL) by increased blood flow and altered anticoagulation regimen...
  6. ncbi Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34+ cell recovery
    Claudia Del Fante
    Servizio di Immunoematologia, Medicina Trasfusionale, Centro di Immunologia dei Trapianti, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    Stem Cells Dev 14:734-9. 2005
    ..platelet depletion versus 48 performed after adjunctive centrifugations to increase platelet depletion of the leukapheresis (LKF) product...
  7. ncbi Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient
    I Ohsawa
    Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
    Clin Nephrol 68:121-4. 2007
    ..We recommend LCAP as candidate therapy for steroid-dependent patients with RA who are on maintenance HD...
  8. ncbi Positive immunomagnetic CD34(+) cell selection in haplo-identical transplants in beta-thalassemia patients: removal of platelets using an automated system
    Francesco Zinno
    Immunohematology Section, Tor Vergata University and SIMT Bambino Gesù Pediatric Hospital, Rome, Italy
    Cytotherapy 12:60-6. 2010
    ....
  9. ncbi Mobilization of peripheral blood stem cells
    Onder Arslan
    Ankara University, Department of Hematology, Blood Bank and Apheresis Unit, Ankara, Turkey
    Transfus Apher Sci 37:179-85. 2007
    ..Processing of more blood in LVL is achieved by an increase of the blood flow rate and an altered anticoagulation regimen with the occurrence of more citrate reactions...
  10. ncbi Why is leukocytapheresis effective in inflammatory bowel diseases?
    Yutaka Kohgo
    J Gastroenterol 39:1226-7. 2004
  11. ncbi Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers
    Ken Yamaji
    Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
    Ther Apher Dial 10:396-403. 2006
    ..Moreover, it appears that investigating the clinical efficacy of pulse LCAP in patients who do not respond to conventional LCAP would be of major significance...
  12. ncbi Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer
    John R Yannelli
    University of Kentucky, Markey Cancer Center, Lexington, KY 40536 0093, USA
    Oncol Rep 22:1459-71. 2009
    The current study characterized peripheral blood mononuclear cells (PBMC) obtained from leukapheresis products of patients with non-small cell lung cancer (NSCLC) for cytokine release, the ability to incorporate tritiated thymidine ..
  13. ncbi Therapeutic leukapheresis in hyperleukocytic leukaemias--the experience of a tertiary institution in Singapore
    D Tan
    Department of Haematology, Singapore General Hospital
    Ann Acad Med Singapore 34:229-34. 2005
    ..They result from endothelial damage secondary to leukostasis. Leukapheresis, which aims to lower the white blood cell (WBC) count, has been used in certain patients to reduce the threat ..
  14. ncbi Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse
    I Yaniv
    Department of Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Israel
    Pediatr Blood Cancer 42:404-9. 2004
    ..CONCLUSIONS: We suggest a possible correlation between the amount of contaminating cells in the harvest and relapse after transplantation. Quantitative RT-PCR studies of the chimeric transcripts are underway to explore this issue...
  15. ncbi Microfluidic diffusive filter for apheresis (leukapheresis)
    Palaniappan Sethu
    Surgical Services and Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School and Shriners Hospital for Children, MA 02114, Boston, USA
    Lab Chip 6:83-9. 2006
    ..b>Leukapheresis is one type of apheresis where leukocytes (white blood cells) are selectively removed...
  16. ncbi Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors
    H Suzuya
    Department of Pediatrics, University of Tokushima Graduate School of Medical Science, Tokushima, Japan
    Vox Sang 89:229-35. 2005
    ..Further validation of these findings in a larger number of donors are needed to establish whether these findings apply to other populations...
  17. ncbi Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
    Cristina Gasparetto
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Cytokine 18:8-19. 2002
    ..study, we sought to determine whether these same cytokines could simultaneously mobilize DCs into the PBSC leukapheresis collection...
  18. ncbi Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis
    Nobuhito Kashiwagi
    Japan Immunoresearch Laboratories, Takasaki, Gunma
    Dig Dis Sci 47:1334-41. 2002
    ....
  19. ncbi Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis
    Takayuki Yamamoto
    World J Gastroenterol 12:520-5. 2006
    ..However, if this treatment prevents hospital admission, re-administration of steroids and surgery, and improves a quality of life of the patients, GMCAP may prove to be cost-effective...
  20. ncbi Isolation of CD4+CD25+ regulatory T cells for clinical trials
    Petra Hoffmann
    Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
    Biol Blood Marrow Transplant 12:267-74. 2006
    ..Here we describe the isolation of CD4+CD25+ T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions...
  21. ncbi Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis
    V D'Ovidio
    Department of Clinical Sciences, GI Unit, Policlinico Umberto I, University of Rome, La Sapienza, Viale del Policlinico 155, Rome, Italy
    Dig Liver Dis 38:389-94. 2006
    ..While several studies have stressed the efficacy of granulocyte-monocyte-apheresis in inducing clinical remission in active ulcerative colitis, few data are available on mucosal features...
  22. ncbi Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration
    Hiroyuki Okada
    Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Ther Apher Dial 10:242-6. 2006
    ....
  23. ncbi Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Gastroenterol 40:482-9. 2006
    ....
  24. ncbi Factors affecting PBSC mobilization and collection in healthy donors
    Daniel Lysak
    Department of Hematology and Oncology, Charles University Hospital, Alej Svobody 80, Plzen 304 60, Czech Republic
    Transfus Apher Sci 33:275-83. 2005
    ..G-CSF had an acceptable short-term safety profile. Our data confirm that apheresis is a safe procedure in healthy including aged donors and suggest that older donors could be poorer mobilizers than younger...
  25. ncbi Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1201, USA
    J Immunother (1997) 28:403-11. 2005
    ..The authors report the ability to selectively deplete CD25+ Treg cells from patient leukapheresis samples using a clinical-grade, large-scale immunomagnetic system...
  26. ncbi Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study
    C Tassi
    Transfusion Medicine Service, Sant'Orsola Hospital, Bologna, Italy
    Bone Marrow Transplant 36:289-94. 2005
    ..14 donors showed persistent, slight lymphocytopenia (mean drop of 13%) until the third year, with recovery in the fourth year of follow-up...
  27. ncbi Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis
    Makoto Naganuma
    Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan
    Inflamm Bowel Dis 10:251-7. 2004
    ..GCAP may also be useful for avoiding re-administration of steroids at the time of relapse. Randomized, controlled clinical trials are needed to confirm these findings...
  28. ncbi Elevation of platelet activation markers and chemokines during peripheral blood stem cell harvest with G-CSF
    Shosaku Nomura
    First Department of Internal Medicine, Kansai Medical University, 10 15 Fumizono cho, Moriguchi, Osaka 570 8507, Japan
    Stem Cells 22:696-703. 2004
    ..Further study is required to determine if a cause-and-effect relationship in their pattern of change exists among them...
  29. ncbi Priapism secondary to leukemia: effective management with prompt leukapheresis
    Allan Ponniah
    Rotherham General Hospital NHS Trust, Rotherham, UK
    Int J Urol 11:809-10. 2004
    ..We discuss the method of leukapheresis (mechanical white cell depletion) to reduce viscosity and achieve detumescence after failed aspiration.
  30. ncbi Factors affecting the efficacy of peripheral blood progenitor cells collections by large-volume leukaphereses with standardized processing volumes
    Uwe Cassens
    Institute of Transfusion Medicine, Department of Medical Informatics and Biomathematics, University Hospital Munster, Germany
    Transfusion 44:1593-602. 2004
    ..Peripheral blood progenitor cell (PBPC) collections should be safe and efficient. Therefore, the influence and risk factors in large-volume leukaphereses (LVL) with standardized blood volumes was investigated...
  31. ncbi Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes
    Abby R Saniabadi
    Japan Immunoresearch Laboratories, Takasaki, Japan
    Ther Apher Dial 7:48-59. 2003
    ..Hence, a long lasting effect on inflammatory cytokine generation, chemokine activities or immunomodulation is likely, but the precise mechanisms involved are not fully understood yet...
  32. ncbi Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis
    Takeshi Tomomasa
    Department of Pediatrics, Gunma University Faculty of Medicine, Maebashi, Japan
    Dig Dis Sci 48:750-4. 2003
    ..5 +/- 2.2 months after the last GCAP while on maintenance therapy, the other 4 were in remission up to 22.8 +/- 18.1 months. In conclusion, GCAP appears to be effective and well tolerated in children with steroid-refractory UC...
  33. ncbi Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study
    E Domenech
    Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Aliment Pharmacol Ther 20:1347-52. 2004
    ..Uncontrolled studies suggest that granulocyteaphaeresis might be useful in the management of active ulcerative colitis...
  34. ncbi Successive double high-dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high-risk pediatric solid tumors: a pilot study in a single center
    K W Sung
    Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Bone Marrow Transplant 31:447-52. 2003
    ..HDCT) in pediatric solid tumors were rescued with peripheral blood stem cells collected during a single leukapheresis round (single-harvest group, SHG)...
  35. ncbi Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim
    Victoria Moncada
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    Transfusion 43:495-501. 2003
    ..CONCLUSION: CD34 cell yields correlate strongly with preapheresis CD34 counts. Based on this analysis, a CD34 count greater than or equal to 8 per microL is the threshold for performing PBPC collections in our institution...
  36. ncbi Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study
    Hiroyuki Hanai
    Department of Endoscopic and Photodynamic Medicine, Hamamatsu University, Japan
    Clin Gastroenterol Hepatol 1:28-35. 2003
    ..GM are major sources of inflammatory cytokines, and in UC they are elevated with increased survival time. We investigated the possibility that reducing the level of these cells might promote remission of active UC...
  37. ncbi [Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open-label multicenter study]
    Hyo Jong Kim
    Departments of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea
    Korean J Gastroenterol 45:34-44. 2005
    ..CONCLUSIONS: Adacolumn was very efficacious in patients with moderate-to-severe active UC refractory to conventional drug therapy, but further assessment is needed...
  38. ncbi Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis
    K Kanke
    Department of Gastroenterology, Dokkyo University School of Medicine, Mibu, Shimotsuga, Tochigi 321 0293, Japan
    Dig Liver Dis 36:811-7. 2004
    ..Recent evidence suggests that peripheral blood granulocytes and monocytes/macrophages have a major role in the exacerbation of ulcerative colitis...
  39. ncbi Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial
    Jorg Emmrich
    Division of Gastroenterology, Department of Internal Medicine, University Hospital of Rostock, Ernst Heydemann Str 6, 18057 Rostock, Germany
    Dig Dis Sci 52:2044-53. 2007
    ..In conclusion, leukocytapheresis may offer a therapeutic option in the induction and the maintenance of remission in chronic active ulcerative colitis...
  40. ncbi Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
    Sumithira Vasu
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:2092-100. 2008
    ..who were prescribed G-CSF dosed at either 10 or 16 microg/kg per day for 5 days followed by large-volume leukapheresis (LVL)...
  41. ncbi Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis
    Takanori Kanai
    Department of Gastroenterology and Hepatology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
    Inflamm Bowel Dis 13:284-90. 2007
    ..In the present study we aimed to clarify how LCAP therapy modifies inflammatory responses by modulating circulating TNF-alpha-producing monocytes...
  42. ncbi Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis
    Lena Oxelmark
    Department of Medicine, Karolinska University Hospital, Solna, Sweden
    Scand J Gastroenterol 42:406-7. 2007
  43. ncbi Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study
    Hitoshi Ikeda
    Department of Pediatric Surgery, Dokkyo University School of Medicine, Koshigaya Hospital, Koshigaya, Japan
    J Pediatr Gastroenterol Nutr 43:592-6. 2006
    ..As a preliminary trial, GCAP was used to taper the dose of steroids in 4 pediatric patients with ulcerative colitis...
  44. ncbi A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis
    Atsushi Sakuraba
    Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    J Gastroenterol 43:51-6. 2008
    ..We performed a pilot open-labeled prospective, randomized, controlled study comparing weekly and an intensive treatment schedule with three treatment sessions per week in the first 2 weeks...
  45. ncbi Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients
    K Takemoto
    Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
    Dig Liver Dis 39:422-9. 2007
    ..The effectiveness of leukocytapheresis against ulcerative colitis has been reported. However, the efficacy of this therapy for steroid-resistant ulcerative colitis patients has hardly been examined...
  46. ncbi Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis
    Ying Jing
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
    Biotechnol Bioeng 96:1139-54. 2007
    ..We tested CD34+ cell immunomagnetic labeling and isolation from fresh leukocyte fraction of peripheral blood (leukapheresis) using the continuous quadrupole magnetic flow sorter (QMS), consisting of a flow channel (SHOT, Greenville, ..
  47. ncbi Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study
    G Bresci
    Gastroenterology Department, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
    Dig Liver Dis 39:430-4. 2007
    ..The aim of our pilot study is to report the efficacy of granulocytapheresis in patients with acute ulcerative colitis with respect to the use of conventional corticosteroids such as methylprednisolone...
  48. ncbi Extracorporeal leukocyte removal therapy for patients with ulcerative colitis
    Masami Kumagai
    Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan
    Pediatr Int 49:431-6. 2007
    ....
  49. ncbi Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC)
    U Cassens
    Department of Transfusion Medicine/Transplantation Immunology, University Hospital Muenster, Muenster, Germany
    Bone Marrow Transplant 28:13-20. 2001
    Although several studies have demonstrated the efficacy of large volume leukapheresis (LVL) to yield high numbers of peripheral blood progenitor cells (PBPC), the mechanisms of stem cell release into circulation and the postulated ..
  50. ncbi Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics
    Hiroshi Miyamoto
    Department of Digestive and Cardiovascular Medicine, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Ther Apher Dial 11:16-21. 2007
    ..However, considering the exacerbation of anemia in patients with severe ulcerative colitis caused by massive melena, monitoring with a less invasive Crit-Line monitor and a vital information monitor might be useful...
  51. ncbi Quantitative expression analysis of HHV-6 cell receptor CD46 on cells of human cord blood, peripheral blood and G-CSF mobilised leukapheresis cells
    Stefanie Thulke
    Charite Universitatsmedizin Berlin, CCM Medizinische Klinik m S Onkologie Hämatologie, Chariteplatz 1, 10117 Berlin, Germany
    Virol J 3:77. 2006
    ..Unexpectedly, CD46 expression on progenitors from G-CSF mobilised leukapheresis products was approximately 20% of that found on comparable cells from untreated cord blood...
  52. ncbi Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes
    Hiroshi Aoki
    Department of Internal of Medicine, Sakura Hospital, Toho University, 564 1 Shimoshizu, Sakura City, Chiba, Japan
    Dig Dis Sci 52:1427-33. 2007
    ..The procedure is associated with sustained immunomodulation. Control studies should strengthen these findings...
  53. ncbi Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia
    Tryggve Ljung
    Department of Gastroentereology and Hepatology, Karolinska University Hospital, Stockholm, Sweden
    Scand J Gastroenterol 42:221-7. 2007
    ....
  54. ncbi Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis
    Hiroyuki Hanai
    Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Japan
    Dig Dis Sci 47:2349-53. 2002
  55. ncbi Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products
    X Y Zhong
    Department of Obstetrics and Gynaecology, University Hospital, Heidelberg, Germany
    J Cancer Res Clin Oncol 125:286-91. 1999
    The work aimed to evaluate the sensitivity and specificity of the cytokeratin (CK) 19 reverse transcriptase/polymerase chain reaction (RT-PCR) for the detection of occult breast cancer in bone marrow and leukapheresis products.
  56. ncbi Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature
    Ridvan Ali
    Division of Hematology, Department of Internal Medicine and Department of Obstetrics and Gynecology, , , , Bursa, Turkey
    Jpn J Clin Oncol 34:215-7. 2004
    ..in the first trimester of her pregnancy with chronic myelogenous leukemia (CML) in chronic phase by using only leukapheresis. She was treated with leukapheresis until her delivery at 36 weeks of gestation...
  57. ncbi Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction
    F Leone
    Ordine Mauriziano, Institute for Cancer Research and Treatment, Candiolo, Italy
    Bone Marrow Transplant 27:517-23. 2001
    ..Peripheral blood (PB), bone marrow (BM), and leukapheresis samples from patients with malignancies other than breast cancer were used as controls...
  58. ncbi Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency
    Sang Kyun Sohn
    Department of Hematology Oncology, Kyungpook National University Hospital, Taegu, South Korea
    J Clin Apher 18:10-5. 2003
    ..factors associated with satisfactory peripheral blood stem cell collection and the efficacy of large-volume leukapheresis (LVL) using femoral vein catheterization to harvest PBSCs with Fenwal CS 3000 Plus from normal healthy donors ..
  59. ncbi Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukapheresis
    R Ali
    Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Uludag University Hospital, 16059 Gorukle Bursa, Turkey
    Ann Hematol 83:61-3. 2004
    ..in the second trimester of her pregnancy with chronic lymphocytic leukemia (CLL) in stage IV by using only leukapheresis. We applied three sessions (courses) of leukapheresis throughout the pregnancy...
  60. ncbi Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study
    T Shimoyama
    Department of Internal Medicine IV, Hyogo College of Medicine, Hyogo, Japan
    J Clin Apher 16:1-9. 2001
    ..This procedure should have the potential to allow tapering the dose of corticosteroids, shorten the time to remission and delay relapse...
  61. ncbi Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study
    Yasuo Suzuki
    Department of Internal Medicene, Sakura Hospital, Faculty of Medicine, Toho University, 564 1 Shimoshizu, Sakura City, Chiba 285 874, Japan
    Dig Dis Sci 49:565-71. 2004
    ..No severe side effects were reported. In conclusion, adsorptive leukocytapheresis should reduce corticosteroid therapy in patients with moderate UC; cases with early-stage active disease may benefit most...
  62. ncbi In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression
    E M Villaron
    Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
    Transfus Apher Sci 37:145-56. 2007
    ..was to evaluate the effect of the chemotherapy on the different progenitor cell subpopulations obtained in the leukapheresis. For this purpose, a combination of immunophenotype and functional assays has been performed in 26 mobilized ..
  63. ncbi [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell trans
    M Klabusay
    Interní hematoonkologická klinika FN, Brno
    Cas Lek Cesk 147:319-24. 2008
    ..Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation...
  64. ncbi Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 6:39. 2008
    ..The HSCs were compared to peripheral blood leukocytes (PBLs) from 7 subjects...
  65. ncbi High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity
    I Gojo
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Bone Marrow Transplant 34:69-76. 2004
    ..A median of 22.39 x 10(6) CD34(+) cells/kg were collected on the first day of leukapheresis (range 0.59-114.71 x 10(6)/kg) in 71 (92%) of patients. Greater marrow plasma cell infiltration (P=0...
  66. ncbi ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience
    M Jerkeman
    Department of Oncology, Lund University Hospital, Sweden
    Eur J Haematol 73:179-82. 2004
    ....
  67. ncbi Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?
    A Gidron
    Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 35:243-6. 2005
    ..We conclude that mobilizing patients with the combination of chemotherapy and GF rather than GF alone leads to leukapheresis being performed when the leukocyte count is low -- in a range that results in optimum CD34+ cell CE...
  68. ncbi Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma
    Jin Hwang Liu
    Division of Hematology Oncology, Taipei Veterans General Hospital, National Yang Ming University School of Medicine, Taipei, Taiwan, ROC
    J Chin Med Assoc 71:279-85. 2008
    ..However, the timing of PBPC harvest following immobilization and factors to predict optimal PBPC yield remain to be explored. We herein analyzed the factors potentially correlated to optimal PBPC mobilization...
  69. ncbi Stem cell mobilization and collection in patients with liver cirrhosis
    S Lorenzini
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 27:932-9. 2008
    ..Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury...
  70. ncbi Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients under
    Asad Bashey
    Division of Blood and Marrow Transplantation, and Biostatistics Core, Rebecca and John Moores UCSD Cancer Center, La Jolla, California, USA
    Transfusion 47:2153-60. 2007
    ..This necessitates the availability of leukapheresis (LP) facilities 7 days a week.
  71. ncbi Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma
    U Steidl
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Bone Marrow Transplant 35:33-6. 2005
    ..These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients...
  72. ncbi Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor
    D Lorenzon
    Clinical and Experimental Haematology Research Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, PN, Italy
    Vox Sang 94:342-50. 2008
    ..We have expanded CD34+ cells from PBPCs obtained from four patients with haematological malignancies and one patient with an Ewing's sarcoma...
  73. ncbi The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients
    Daniela Damiani
    Chair and Division of Hematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Adv Clin Path 6:11-6. 2002
    ....
  74. ncbi Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, and the Mark O Hatfield Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 47:1250-3. 2007
    ..Even patients who have clinically recovered from aplastic anemia have diminished hematopoietic progenitor cells, so the practicability of PBPC mobilization in these individuals is unknown...
  75. ncbi Evaluation of the COM.TEC cell separator in predicting the yield of harvested CD34+ cells
    Kamran Movassaghi
    Institute of Transfusion Medicine, Charite University Hospital, Humboldt University, Berlin, Germany
    Transfusion 47:824-31. 2007
    ..was performed with the intention to evaluate the exactness of the predicted CD34+ cell yield calculated by two leukapheresis programs of the cell separator COM...
  76. ncbi Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency
    Stefano Fontana
    Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    Transfusion 46:1408-16. 2006
    ..Individual adaptation of processed patient's blood volume (PBV) should reduce number and/or duration of autologous peripheral blood progenitor cell (PBPC) collections...
  77. ncbi A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma
    Francois Lefrere
    Service d Hématologie Adultes, Centre d Investigation Clinique Hôpital Necker, Direction de la Recherche Clinique, AP HP, Paris, France
    Haematologica 91:550-3. 2006
    ..7%, 91%, 93.9 and 96.4%, respectively. Low G-CSF doses may be used with a similar probability of success as conventional doses and could allow significant savings...
  78. ncbi Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization
    P Fu
    Department of Epidemiology and Biostatistics, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Bone Marrow Transplant 38:189-96. 2006
    ..1 cells x 10(6)/l (s.d. = 3.9, r = 0.3-37) and mean CD34+ cells collected were 5.3 x 10(6) cells/kg/leukapheresis procedure (s.d. = 7.0, r = 0.03-53). Yields correlated with pre-mobilization CD34+ cells x 10(6)/l (r = 0...
  79. ncbi Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour
    J Vermeulen
    , Institut Curie, Paris, France
    Br J Cancer 95:1326-33. 2006
    ..Tumour cell contamination of PBSC collection is rare and does not seem to be associated with a significantly poorer EFS or OS in this high-risk population...
  80. ncbi A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma
    Ingmar Bruns
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany
    Transfusion 46:180-5. 2006
    ..Because no dose dependency was seen at these dose levels, this might be also true for even smaller doses...
  81. ncbi Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF
    M T Delamain
    Hematology-Hemotherapy Center, State University of Campinas, P.O. Box 6198, Barao Geraldo, 13081-970 Campinas, SP, Brazil
    Transfus Apher Sci 34:33-40. 2006
    ....
  82. ncbi Prediction of target CD34 positive cells following leukopheresis in children with neuroblastoma
    Henrik Schroeder
    Department of Pediatrics, University Hospital of Aarhus, Aarhus, Denmark
    Pediatr Blood Cancer 46:786-92. 2006
    ..In children it is important to be able to ascertain when to start the leukopheresis in order to keep the number of procedures to a minimum...
  83. ncbi Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors
    Frank Kroschinsky
    University Hospital Dresden, 1st Medical Department, Dresden, Germany
    Haematologica 90:1665-71. 2005
    ..The pegylated form of filgrastim (pegfilgrastim) has a longer elimination half-life because of decreased serum clearance and might be a convenient alternative for stem cell mobilization...
  84. ncbi Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission
    D Strodtbeck
    Medizinische Klinik und Poliklinik I, , Dresden, Germany
    Bone Marrow Transplant 36:1083-8. 2005
    ..Additionally, a minimum of three chemotherapy cycles before ABSCT seems to be associated with an improved outcome...
  85. ncbi Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation
    L Statkute
    Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Bone Marrow Transplant 39:317-29. 2007
    ..When adjusted for CD34(+) cell/kg dose, patients treated with a myeloablative regimen had significantly slower WBC and platelet recovery compared to non-myeloablative regimens...
  86. ncbi Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers
    R Goterris
    Hematology and Medical Oncology Service, , University of Valencia, Valencia, Spain
    Bone Marrow Transplant 36:847-53. 2005
    ....
  87. ncbi Hourly monitoring of circulating CD34+ cells to optimize timing of autologous apheresis in pediatric patients
    K Bochennek
    Pediatric Hematology and Oncology of Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main, Germany
    Bone Marrow Transplant 36:481-9. 2005
    ..mobilization of CD34+ cells and white blood cells in the peripheral blood (PB) of 20 pediatric patients before leukapheresis. The monitoring schedule covered 12 h, with blood samples taken before and at 2, 4, 5, 6, 7, 8, 10 and 12 h ..
  88. ncbi Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis
    J P Rinn
    , Baldingerstrasse, , Marburg, Germany
    Ann Hematol 85:38-44. 2006
    ..The irradiated bone marrow volume and the number of CD34+ cells per kilogram of body weight in the first leukapheresis product showed no correlation...
  89. ncbi Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors
    Natalia Lopez-Holgado
    Department of Hematology, Hospital Clinico Universitario de Salamanca, Salamanca, Spain
    Haematologica 90:353-9. 2005
    ..There is wide interindividual variation in progenitor cell mobilization. The present study was aimed to analyze steady state hematopoiesis in healthy donors and its influence on hematopoietic progenitor cell (HPC) mobilization...
  90. ncbi Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia
    Gwen L Nichols
    Stem Cells Dev 14:3-5. 2005
  91. ncbi ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF
    J-L Lee
    Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    Bone Marrow Transplant 35:449-54. 2005
    ..007). These results indicate that ESHAP plus G-CSF is an excellent mobilization regimen in patients with relapsed and poor-risk aggressive NHL...
  92. ncbi The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation
    A L Basquiera
    Division of Hematology and Oncology, Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina
    J Clin Apher 21:92-5. 2006
    ..Between March 1999 and August 2003, patients with hematological and solid malignancies who underwent leukapheresis for autologous bone marrow transplantation were prospectively evaluated...
  93. ncbi Clinical impact of a new automated system employed for peripheral blood stem cell collection
    Claudia Del Fante
    Immunohaematology and Transfusion Service, Center for Transplant Immunology, IRCCS Policlinico S. Matteo, Pavia, Italy
    J Clin Apher 21:227-32. 2006
    ..program that provides the ability to predict the total number of CD34(+) cells collected, based on the pre-leukapheresis CD34(+) cell count in peripheral blood...
  94. ncbi Granulocyte colony-stimulating factor alone at 12 microg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients
    J Sevilla
    , Madrid, Spain
    Bone Marrow Transplant 30:417-20. 2002
    ..6%) after a single large volume leukapheresis. In conclusion, this mobilization schedule allows safe and efficient collection of the minimum target CD34(+) ..
  95. ncbi Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest
    Jae-Lyun Lee
    Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-040, Korea
    J Korean Med Sci 18:27-35. 2003
    ..7% and 81.1%, respectively. In the clinical practice setting, applying variable cutoff values of HPC would be a useful tool to predict the optimal timing of PBPC collection...
  96. ncbi Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft
    Nimrod Schwella
    Division of Hematology Oncology, Department of Internal Medicine, Philipps University Hospital, Marburg, Germany
    Transfusion 43:259-64. 2003
    ..However, there are no data available concerning the collection of PBPCs after high-dose chemotherapy (HDCT) and autologous hematopoietic transplantation in a larger series...
  97. ncbi Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma
    M Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Bone Marrow Transplant 28:923-7. 2001
    ..These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs...
  98. ncbi [Analysis of hematological findings affecting the efficiency of the autologous peripheral blood stem cells harvest]
    K Nakata
    Unit of Blood Transfusion Medicine, University Hospital, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan
    J UOEH 23:411-20. 2001
    ..These findings suggested that IMA-% and IMA-Co were the most useful factors for successful PBSCH widely mobilized by chemotherapy with G-CSF in general hospitals...
  99. ncbi Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood
    Jennette A Sakoff
    Department of Medical Oncology, Newcastle Mater Misericordiae Hospital, Newcastle, Locked Bag No 7, Hunter Region Mail Center, 2310, NSW, Australia
    Leuk Lymphoma 43:2017-20. 2002
    ..83, P < 0.001). Thus, telomere length in haemopoietic stem cells can be determined from that of whole or fractionated PB in future studies of haematological disorders...
  100. ncbi Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide
    Giorgio Lambertenghi Deliliers
    Dipartimento di Ematologia, Centro Trapianri di Midollo, Ospedale Maggiore IRCCS, Via Francesco Sforza 35, 20122, Milan, Italy
    Leuk Lymphoma 43:1957-60. 2002
    ..This does not imply that low-dose CTX is the best mobilising regimen for all patients, and the identification of prognostic factors predicting mobilising potential may help in choosing the best individualised regimen...
  101. ncbi Effect of G-CSF on peripheral blood progenitor cell mobilization and collection from healthy donors
    W Chaisiripoomkere
    Research Center Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Asian Pac J Allergy Immunol 19:183-90. 2001
    ..The correlation between the number of CD34+ cells/kg, CFU-GM/kg and MNC/kg found in the harvested product and CD34 cells can be used for determining the necessary amount of progenitor cells for transplantation...

Research Grants66

  1. Bone Marrow Angioblasts for Myocardial Vasculogenesis
    Silviu Itescu; Fiscal Year: 2006
    ..Phenotypic studies will be performed by flow cytometry of human bone marrow-derived cells obtained by leukapheresis after G-CSF mobilization...
  2. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2002
    ..We will also generate potentially therapeutic DC from leukapheresis products of CRC patients (some of them may be pretreated with 3H1 vaccine), and pulse them with the anti-Id ..
  3. EGFRBi-armed ATC for Advanced NSCLC: A Phase I Trial
    Abby L Maizel; Fiscal Year: 2010
    ..ATC will be expanded for 14 days from a leukapheresis product of each patient, armed with EGFRBi, cryopreserved, and infused in 8 divided doses...
  4. EGFRBi-armed ATC for Advanced NSCLC: A Phase I Trial
    Abby Maizel; Fiscal Year: 2007
    ..ATC will be expanded for 14 days from a leukapheresis product of each patient, armed with EGFRBi, cryopreserved, and infused in 8 divided doses...
  5. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2002
    ..It will also be used to investigate the incidence and significance of tumor contamination in the leukapheresis products collected for peripheral blood stem cell transplantation (PBSCT) in the setting of relapsed and ..
  6. Amotosalen PCT of Leukapheresis Units for GvHD Therapy
    JOHN HEARST; Fiscal Year: 2007
    ..In addition we are associated with three clinical trials utilizing Amotosalen-HCI photochemically treated leukocytes for use in bone marrow transplantation and as a vaccine for Epstein-Barr virus. ..
  7. Adjuvant immunotherapy for non-small cell lung cancer
    Michael Roth; Fiscal Year: 2005
    ..DC precursors will be harvested by leukapheresis and differentiated ex vivo with GM-CSF and IL-4...
  8. IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy
    Dan Douer; Fiscal Year: 2007
    ..procedure involving several steps that include mobilization with growth factors, multiple sessions of leukapheresis (each lasting several hours) to obtain sufficient hematopoietic stem cells (HSC), processing and ..
  9. TOLERANCE TO VASCULARIZED ALLOGRAFTS IN MINISWINE
    David Sachs; Fiscal Year: 2007
    ..Finally, we have found that the treatment of tolerant animals with DST and leukapheresis, required for successful adoptive transfer of their tolerance, also leads to loss of the tolerant state...
  10. Immunotherapy for Renal Cell Carcinoma
    Marc Ernstoff; Fiscal Year: 2005
    ..Eligible and consented patients with metastatic RCC will undergo leukapheresis to obtain peripheral blood monocyte derived DCs...
  11. Monocyte Traffic and Neuropathogenesis of AIDS
    Kenneth Williams; Fiscal Year: 2006
    ..Studies in aim 2 propose to use leukapheresis, in normal and SIV infected animals to directly assess the role of specific monocyte subsets to traffic to the ..
  12. Monocyte Traffic and Neuropathogenesis of AIDS
    Kenneth Williams; Fiscal Year: 2007
    ..Studies in aim 2 propose to use leukapheresis, in normal and SIV infected animals to directly assess the role of specific monocyte subsets to traffic to the ..
  13. Monocyte Traffic and Neuropathogenesis of AIDS
    Kenneth C Williams; Fiscal Year: 2010
    ..Studies in aim 2 propose to use leukapheresis, in normal and SIV infected animals to directly assess the role of specific monocyte subsets to traffic to the ..